ADMET & DMPK
ADMET & DMPK
Cilt: 4 Sayı: 3
ADME/DMPK in the development and use of tyrosine and serine-threonine kinase inhibitors
Cilt: 4, Sayı: 3 Sayfalar 182-185 Godefridus Peters, Kin Tam ADMET & DMPK
Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
Cilt: 4, Sayı: 3 Sayfalar 186-211 Jonathan R. Thompson, Smitha P. Menon, Grace K. Dy ADMET & DMPK
Cardiovascular safety of protein kinase inhibitors: putting their “QT-phobia” in perspective
Cilt: 4, Sayı: 3 Sayfalar 212-231 Rashmi Shah ADMET & DMPK
Cross talk of c-Jun N-terminal kinase and p38 map kinase modulate insulin and TNFα-stimulated VCAM-1 expression in rat aorta endothelial cells
Cilt: 4, Sayı: 3 Sayfalar 232-240 Gregory B. Pott, Mark Tsurudome, Jamie Bui, Chelsea Gardner, Marc Goalstone ADMET & DMPK
Dose optimization of ceftriaxone-vancomycin combination using fractional inhibitory concentration kinetics in resistant bacteria
Cilt: 4, Sayı: 3 Sayfalar 241-260 Vishnu D Sharma, Aman Singla, Manu Chaudhary, Mukesh Kumar, Anuj Bhatnagar, Shailesh Kumar, Manish Taneja ADMET & DMPK
Evaluation of P-glycoprotein expression in pain relevant tissues: understanding translation of efflux from preclinical species to human
Cilt: 4, Sayı: 3 Sayfalar 261-268 Renu Singh Dhanikula, Cyrla Hoffert, Rebecca Grant, Denis Projean, Rosemarie Panetta, Dajan O’Donnell, Marie Roumi ADMET & DMPK
Evaluation of pharmacokinetic and pharmacodynamic interaction between repaglinide and atazanavir in healthy, diabetic and hepatic impaired rats: possible inhibition of CYP3A, OATP, and P-glycoprotein transporters
Cilt: 4, Sayı: 3 Sayfalar 269-279 Thirumaleswara Goud, Srinivas Maddi, Nayakanti Devanna, Thatipamula Rajendra Prasad ADMET & DMPK
Dergiye ait tüm sayılar